Scarica l'app Stockscreener
127.86
2.68%
-3.52
Dopo l'orario di chiusura:
127.86
Glaukos Corporation Borsa (GKOS) Ultime notizie
Glaukos (NYSE:GKOS) Shares Gap DownHere's What Happened - MarketBeat
Glaukos (NYSE:GKOS) Posts Earnings Results, Beats Expectations By $0.20 EPS - MarketBeat
Earnings call: Glaukos reports strong Q3 growth, raises 2024 guidance - Investing.com
Glaukos (GKOS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Glaukos (NYSE:GKOS) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says - MarketBeat
GKOS Stock Declines Despite Q3 Earnings & Revenues Beat Estimates - Yahoo Finance
Piper Sandler reaffirms stock target on Glaukos post-Q3 beat - Investing.com
Glaukos price target raised to $145 from $135 at Wells Fargo - TipRanks
BTIG reiterates Buy on Glaukos stock as strong iDose sales support growth outlook - Investing.com
Glaukos Co. (NYSE:GKOS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Glaukos Corp (GKOS) Q3 2024 Earnings Call Highlights: Record Sal - GuruFocus.com
Glaukos Corp (GKOS) Q3 2024 Earnings Call Highlights: Record Sales and Raised Guidance Amid ... - Yahoo Finance
Glaukos Reports Net Sales Increase of 24 Percent in Third Quarter 2024 Behind Strong Glaucoma Sales - Vision Monday
Glaukos reports Q3 adjusted EPS (28c), consensus (48c) - TipRanks
Glaukos Corp. Reports Record Third-Quarter Sales Growth - TipRanks
Glaukos Corp earnings beat by $0.20, revenue topped estimates - Investing.com
Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Glaukos: Q3 Earnings Snapshot - San Antonio Express-News
Glaukos Corp (GKOS) Q3 2024 Earnings: EPS of ($0.39) Beats Estimates, Revenue Surges to $96.7 Million - GuruFocus.com
Glaukos Reports Record Sales Despite Net Loss - TipRanks
Q3 2024 Glaukos Corp Earnings Call Transcript - GuruFocus.com
Glaukos Announces Third Quarter 2024 Financial Results - StockTitan
Glaukos Co. (NYSE:GKOS) Shares Sold by New York State Common Retirement Fund - MarketBeat
Glaukos president sells $316,156 in stock By Investing.com - Investing.com Australia
Glaukos Co. (NYSE:GKOS) COO Sells $316,156.75 in Stock - MarketBeat
Glaukos president sells $316,156 in stock - Investing.com
Earnings To Watch: Glaukos Corp (GKOS) Reports Q3 2024 Result - GuruFocus.com
Possible Bearish Signals With Glaukos Insiders Disposing Stock - Simply Wall St
Creative Planning Purchases 4,937 Shares of Glaukos Co. (NYSE:GKOS) - MarketBeat
Is Glaukos stock ready for a breakout with iDose demand? Jefferies thinks so By Investing.com - Investing.com South Africa
Glaukos stock soars to all-time high of $136.74 amid robust growth By Investing.com - Investing.com South Africa
Glaukos (NYSE:GKOS) Sets New 1-Year HighHere's Why - MarketBeat
Glaukos stock soars to all-time high of $136.74 amid robust growth - Investing.com
Is Glaukos stock ready for a breakout with iDose demand? Jefferies thinks so - Investing.com Canada
Glaukos (GKOS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
Glaukos (GKOS) Scheduled to Post Earnings on Monday - MarketBeat
Glaukos Co. (NYSE:GKOS) Stake Boosted by Assenagon Asset Management S.A. - MarketBeat
Taylor Frigon Capital Management LLC Has $3.64 Million Stake in Glaukos Co. (NYSE:GKOS) - MarketBeat
Allspring Global Investments Holdings LLC Has $50.89 Million Stock Position in Glaukos Co. (NYSE:GKOS) - MarketBeat
Glaukos shares maintain buy rating as Truist sees iDose boosting company’s growth trajectory into 2025 - Investing.com Australia
Long Term Trading Analysis for (GKOS) - Stock Traders Daily
Glaukos (NYSE:GKOS) Upgraded by StockNews.com to "Hold" - MarketBeat
GKOS Stock Rises on Positive Phase 3 Confirmatory Trial for Epioxa - MSN
Exchange Traded Concepts LLC Buys New Stake in Glaukos Co. (NYSE:GKOS) - MarketBeat
Glaukos Corp (GKOS) Stock Price Up 3.09% on Oct 18 - GuruFocus.com
Glaukos eyes FDA approval for ocular therapy after Phase III win - Pharmaceutical Technology
Glaukos shares maintain Overweight rating from Piper Sandler - Investing.com
Glaukos shares maintain Overweight rating from Piper Sandler By Investing.com - Investing.com South Africa
Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety - BioSpace
Glaukos announces positive results in keratoconus treatment trial - Investing.com
Glaukos says Epioxa Phase 3 confirmatory trial meets primary endpoint - TipRanks
0.47%
1.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):